Treatment strategies for nodal and gastrointestinal follicular lymphoma: Current status and future development

doi:10.3748/wjg.v16.i44.5543

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 44

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4348)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-5) series.

Item

Count

PDF

427

HTML

3660

Tables (1-5)

261

Sum=4348

Nov 28, 2010 (publication date) through Feb 5, 2025

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Nov 28, 2010; 16(44): 5543-5554
Published online Nov 28, 2010. doi: 10.3748/wjg.v16.i44.5543

Table 5 Results of phase III clinical trials of idiotype vaccines in follicular lymphoma

Study	No. of patients, target disease	Regimen of induction therapy	Eligibility	Vaccine type	Vaccine production methodology	Primary end point
	No. of patients, target disease	Regimen of induction therapy			Vaccine production methodology	Survival types, P-value, significance
Biovest	n = 177, untreated FL	PACE or R-CHOP	CR	Id-KLH/GM-CSF	Rescue hybridoma	Disease-free survival, P > 0.05, not significant
Genitope	n = 287, untreated FL	CVP	CR, PR	Id-KLH/GM-CSF	Recombinant DNA	Progression-free survival, P > 0.05, not significant
Favrille	n = 349, untreated or recurrent FL	Rituximab	CR, PR, SD	Id-KLH/GM-CSF	Recombinant DNA	Time to progression, P > 0.05, not significant

FL: Follicular lymphoma; PACE: Prednisolone, doxorubicin, cyclophosphamide and etoposide; R-CHOP: Rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisolone; CVP: Cyclophosphamide, vincristine, prednisolone; CR: Complete response; PR: Partial response; SD: Stable disease; Id-KLH: Idiotype-keyhole limpet hemocyanin; GM-CSF: Granulocyte-macrophage colony stimulating factor.

Citation: Watanabe T. Treatment strategies for nodal and gastrointestinal follicular lymphoma: Current status and future development. World J Gastroenterol 2010; 16(44): 5543-5554
URL: https://www.wjgnet.com/1007-9327/full/v16/i44/5543.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i44.5543